ProCE Banner Activity

CE / CME

Advances in Prophylaxis and Treatment of Acute and Chronic GVHD: Expert Guidance and Practical Considerations

Get up to date on the latest multidisciplinary strategies to improve prophylaxis and treatment outcomes in patients with acute and chronic GVHD.

ABIM MOC : maximum of 1.00 Medical Knowledge MOC point(s)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 29, 2021

Expiration: July 28, 2022

No longer available for credit.

Share

Faculty

Amin Alousi

Amin Alousi, MD

Professor
Division of Cancer Medicine
Department of Stem Cell Transplantation
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sally Arai

Sally Arai, MD

Associate Professor of Medicine
Blood and Marrow Transplantation and Cellular Therapy
Stanford University Medical Center
Stanford, California

Corey Cutler

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Incyte Corporation

Target Audience

This program is intended for transplant specialists, hematologist-oncologists, and other clinicians involved in the management of patients with GVHD.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review recent advances in our understanding of the underlying pathophysiology of GVHD and ongoing efforts to identify novel biomarkers and prognostic indicators to optimize clinical outcomes
  • Appraise the current and emerging prophylactic strategies for the prevention of GVHD and the latest evidence on innovative therapies for management of acute or chronic, steroid-refractory GVHD
  • Apply the most optimal evidence-based strategies for acute and chronic, previously untreated, and steroid-refractory GVHD based on individual patient and disease characteristics
  • Recognize adverse events and toxicities associated with prophylactic strategies and therapeutic approaches and use this information to develop supportive care plans for patients with GVHD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Amin Alousi, MD

Professor
Division of Cancer Medicine
Department of Stem Cell Transplantation
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amin Alousi, MD, has disclosed that he has received consulting fees from Alexion, Kadmon, Medexus, and Prolacta, fees for non-CME services from Therakos, and funding for research from Incyte.

Sally Arai, MD

Associate Professor of Medicine
Blood and Marrow Transplantation and Cellular Therapy
Stanford University Medical Center
Stanford, California

Sally Arai, MD, MS, has no relevant conflicts of interest to report.

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey S. Cutler, MD, MPH, FRCPC, has disclosed that he has received consulting fees from CareDx, Fresenius-Kabi, Incyte, Janssen, Jazz, Kadmon, and Mesoblast, and other financial/material support from Omeros.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 29, 2021, through July 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of clinicians in treating patients with hematologic malignancies with or at risk of GVHD.